Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LGH447 in AML or High Risk MDS
NCT02078609Phase 1Completed
- Sponsor
- Novartis
- Start
- Mar 2014
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of PIM447 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Novartis. Primary endpoint: Incidence rate of dose limiting toxicities (DLTs) at 28 days. Started Mar 2014; status: completed.
02
Drugs
PIM447
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02078609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02078609.